Identification of novel fibroblast growth factor receptor 3 gene mutations in actinic cheilitis and squamous cell carcinoma of the lip

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 107, Issue 4, 2009, Pages 535-541

  Chou, Annie ^a   Dekker, Nusi ^a   Jordan, Richard C K ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3;

ADULT; AGED; ARTICLE; CHEILITIS; ENZYME IMMUNOASSAY; GENETICS; HUMAN; LIP TUMOR; MALE; MIDDLE AGED; NUCLEOTIDE SEQUENCE; POINT MUTATION; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA; SUNLIGHT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CHEILITIS; DNA MUTATIONAL ANALYSIS; HUMANS; IMMUNOENZYME TECHNIQUES; LIP NEOPLASMS; MALE; MIDDLE AGED; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SUNLIGHT;

EID: 62849109580     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2008.12.050     Document Type: Article

References (32)

1. Johnson D.E., and Williams L.T. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 60 (1993) 1-41
2. Friesel R.E., and Maciag T. Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J 9 (1995) 919-925
3. Bernard-Pierrot I., Brams A., Dunois-Larde C., Caillault A., Diez de Medina S.G., Cappellen D., et al. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis 27 (2006) 740-747
4. Schlessinger J., and Ullrich A. Growth factor signaling by receptor tyrosine kinases. Neuron 9 (1992) 383-391
5. Heldin C.H. Dimerization of cell surface receptors in signal transduction. Cell 80 (1995) 213-223
6. Eswarakumar V.P., Lax I., and Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16 (2005) 139-149
7. Ornitz D.M. FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays 22 (2000) 108-112
8. Delezoide A.L., Benoist-Lasselin C., Legeai-Mallet L., Le Merrer M., Munnich A., Vekemans M., et al. Spatio-temporal expression of FGFR 1, 2 and 3 genes during human embryo-fetal ossification. Mech Dev 77 (1998) 19-30
9. Chellaiah A.T., McEwen D.G., Werner S., Xu J., and Ornitz D.M. Fibroblast growth factor receptor (FGFR) 3. Alternative splicing in immunoglobulin-like domain III creates a receptor highly specific for acidic FGF/FGF-1. J Biol Chem 269 (1994) 11620-11627
10. Ornitz D.M., Xu J., Colvin J.S., McEwen D.G., MacArthur C.A., Coulier F., et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem 271 (1996) 15292-15297
11. Webster M.K., and Donoghue D.J. FGFR activation in skeletal disorders: too much of a good thing. Trends Genet 13 (1997) 178-182
12. Passos-Bueno M.R., Wilcox W.R., Jabs E.W., Sertie A.L., Alonso L.G., and Kitoh H. Clinical spectrum of fibroblast growth factor receptor mutations. Hum Mutat 14 (1999) 115-125
13. Robertson S.C., Tynan J., and Donoghue D.J. RTK mutations and human syndromes: when good receptors turn bad. Trends Genet 16 (2000) 368
14. Karoui M., Hofmann-Radvanyi H., Zimmermann U., Couvelard A., Degott C., Faridoni-Laurens L., et al. No evidence of somatic FGFR3 mutation in various types of carcinoma. Oncogene 20 (2001) 5059-5061
15. Cappellen D., De Oliveira C., Ricol D., de Medina S., Bourdin J., Sastre-Garau X., et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 23 (1999) 18-20
16. Wu R., Connolly D., Ngelangel C., Bosch F.X., Munoz N., and Cho K.R. Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix. Oncogene 19 (2000) 5543-5546
17. Logie A., Dunois-Larde C., Rosty C., Levrel O., Blanche M., Ribeiro A., et al. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet 14 (2005) 1153-1160
18. van der Wijk T., Overvoorde J., and den Hertog J. H2O2-induced intermolecular disulfide bond formation between receptor protein-tyrosine phosphatases. J Biol Chem 279 (2004) 44355-44361
19. Zhang Y., Hiraishi Y., Wang H., Sumi K.S., Hayashido Y., Toratani S., et al. Constitutive activating mutation of the FGFR3b in oral squamous cell carcinomas. Int J Cancer 117 (2005) 166-168
20. Hafner C., van Oers J.M., Hartmann A., Landthaler M., Stoehr R., Blaszyk H., et al. High frequency of FGFR3 mutations in adenoid seborrheic keratoses. J Invest Dermatol 126 (2006) 2404-2407
21. Hernandez S., Toll A., Baselga E., Ribe A., Azua-Romeo J., Pujol R.M., et al. Fibroblast growth factor receptor 3 mutations in epidermal nevi and associated low grade bladder tumors. J Invest Dermatol 127 (2007) 1664-1666
22. Wakulich C., Jackson-Boeters L., Daley T.D., and Wysocki G.P. Immunohistochemical localization of growth factors fibroblast growth factor-1 and fibroblast growth factor-2 and receptors fibroblast growth factor receptor-2 and fibroblast growth factor receptor-3 in normal oral epithelium, epithelial dysplasias, and squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 93 (2002) 573-579
23. Menta Simonsen Nico M., Rivitti E.A., and Lourenço S.V. Actinic cheilitis: Histologic study of the entire vermilion and comparison with previous biopsy. J Cutan Pathol 34 (2007) 309-314
24. Ostwald C., Gogacz P., Hillmann T., Schweder J., Gundlach K., Kundt G., et al. p53 mutational spectra are different between squamous-cell carcinomas of the lip and the oral cavity. Int J Cancer 88 (2000) 82-86
25. Cavalcante A.S., Anbinder A.L., and Carvalho Y.R. Actinic cheilitis: clinical and histological features. J Oral Maxillofac Surg 66 (2008) 498-503
26. Naski M.C., Wang Q., Xu J., and Ornitz D.M. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet 13 (1996) 233-237
27. Martinez A., Brethauer U., Rojas I.G., Spencer M., Mucientes F., Borlando J., et al. Expression of apoptotic and cell proliferation regulatory proteins in actinic cheilitis. J Oral Pathol Med 34 (2005) 257-262
28. van Rhijn B.W., van Tilborg A.A., Lurkin I., Bonaventure J., de Vries A., Thiery J.P., et al. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in nonlethal skeletal disorders. Eur J Hum Genet 10 (2002) 819-824
29. Hafner C., Hartmann A., and Vogt T. FGFR3 mutations in epidermal nevi and seborrheic keratoses: lessons from urothelium and skin. J Invest Dermatol 127 (2007) 1572-1573
30. Hafner C., Vogt T., and Hartmann A. FGFR3 mutations in benign skin tumors. Cell Cycle 5 (2006) 2723-2728
31. Illmer T., and Ehninger G. FLT3 kinase inhibitors in the management of acute myeloid leukemia. Clin Lymphoma Myeloma 8 Suppl 1 (2007) S24-S34
32. Chen J., Lee B.H., Williams I.R., Kutok J.L., Mitsiades C.S., Duclos N., et al. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene 24 (2005) 8259-8267